Objective: To investigate the effectiveness of statin therapy and to compare the effectiveness results of this study with the reported efficacy of the corresponding data from randomized clinical trials in a moderate-to-high risk coronary heart disease (CHD) managed care population. Methods: Subjects, ≥18 years old, with a new hyperlipidemia diagnosis or a new prescription claim for a lipidlowering medication (LLM) between January 1, 1999 and March 31, 2001 were followed for 12 months. Subjects were classified into six medication categories of LLM use based partly on efficacy levels on package inserts. CHD risk factors were measured in the 24-month period prior, and subjects were required to have an established CHD or a CHD-related condition, or have two or more CHD risk factors.
tions ranged from a 32 mg/dL decrease in the low-efficacy groups to a 57 mg/dL decrease in the high efficacy statin group; percent reductions ranged from a 19% reduction from baseline to a 32% reduction from baseline, respectively. Less than half of subjects (47%) reached LDL goals set forth by NCEP Adult Treatment Panel (ATP III) guidelines, however, the rate of reaching goal increased as statin efficacy increased. Conclusions: While a dose-response relationship was observed, the effectiveness of statin therapy was less than stated in package labeling and only 72% of the users of the highest efficacy statins reached their ATP III goal. LLM use was inconsistent with that recommended by the NCEP ATP III CHD risk assessment. Hyperlipidemia treatment in the managed care setting remains in need of improvement. Keywords: ATP III, CHD risk, hyperlipidemia, lipidlowering, managed care, statin.
Background
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States. Currently, there are 61.8 million Americans with CVD. Approximately 12.9 million are afflicted with coronary heart disease (CHD) [1] and more than a million new CHD events occurred in 2002. Nationally, 2003 estimates are that CVD and stroke account for $351.8 billion in direct and indirect costs, with $129.9 billion attributable to CHD. The estimated total direct costs of CHD are $61.2 billion with hospitalization as the major cost driver costing $34.2 billion annually [2] . Benchmark stud-ies in managed care populations indicate that the average cost per enrollee per year for CHD is approximately $4000 [3] .
Decades of epidemiologic research have demonstrated a causal relation between high total cholesterol levels, particularly increases in low-density lipoprotein cholesterol (LDL-C), and the risk of CHD [4] . The beneficial effects of a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (or statin) in reduction of CHD morbidity and mortality have been well established [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] . Despite the availability of these effective therapies, CHD remains highly prevalent. The high incidence and prevalence of CHD may be due to the continuing high cholesterol levels. The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) recommends initiation of lipidlowering therapy in conjunction with therapeutic life style change for patients at high risk for CHD as well those with established disease. The ATP III guidelines update the previous NCEP recommendations and suggest "Recommendations for special populations such as patients with CHD, patients at high risk for developing CHD, patients with diabetes, women, older Americans, young adults, and racial and ethnic groups . . ." [17] .
There has been very little change in total cholesterol levels in more than a decade despite public awareness campaigns to reduce cholesterol. In a 1999-2000 National Health and Nutrition Examination Survey (NHANES), the average cholesterol level among US adults was 203 mg/dL of blood. The findings, published by the American Heart Association (AHA) journal Circulation, are based on cholesterol levels of about 4000 men and women who were participating in the NHANES survey from 1999 to 2000. Their cholesterol levels were compared with national data collected from more than 15,000 people during a similar survey conducted between 1988 and 1994. For all adults, the age-adjusted average total cholesterol concentration decreased from 205 mg/dL to 203 mg/dL between the two surveys. Comparing the 1988-1994 NHANES survey to the 1976-1980 NHANES survey, age-adjusted cholesterol levels dropped by 8 mg/dL [18] .
A review of research done in managed care settings over the last decade reveals a large and consistent performance gap in cholesterol management, in which most at-risk subjects are undertreated [19] [20] [21] [22] [23] . Studies of statin therapy in actual clinical practice have identified a performance gap in the pharmacological management of dyslipidemia when compared with the expectations generated by the results of clinical trials of these therapies. In a study of simvastatin, atorvastatin, and pravastatin patients who were enrolled in a group cardiology practice with case management, Frolkis and colleagues noted that subjects achieved only 79% of the expected reduction in LDL-C based on package labeling. The authors attributed this failure to achieve expected levels of LDL-C reduction on variations in patient compliance with therapy (both medication and dietary recommendations) [24] . Pearson et al. noted that only 38% of subjects enrolled in the Lipid Treatment Assessment Project, who were receiving lipid-lower therapy (including statins), reached NCEP-specified targets for LDL-C. These authors cite the failure of subjects to be prescribed adequate treatments as a primary cause of the failure to achieve LDL-C goals [19] .
The current research adds to the literature by examining the management of dyslipidemia in realworld clinical practice based on ATP III guidelines and current data from a national managed care organization. The objectives of this study were: 1) to assess the effectiveness of lipid-lowering therapies in a real-world setting; and 2) to compare the effectiveness results of this study with the reported efficacy of the corresponding data from randomized clinical trials (RCTs). Effectiveness was measured by the percent reduction in LDL-C and by the proportion of subjects reaching an ATP III-established LDL-C goal.
Methods

Data Source
The current study was based on claims data from several health plans located in various geographic areas of the United States that were affiliated with Ingenix, Inc. The study sample was selected from a database which contains more than 5 million annual covered lives, and was limited to subjects ≥18 years of age with integrated laboratory results, pharmacy, and medical claims data with service dates from January 1, 1997 to March 31, 2001. All plans were noncapitated, managed fee-for-service plans. Laboratory results were not available in the database before January 1, 1999 and cholesterol results were available for approximately 10% of subjects after January 1, 1999. The database complies with the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and Ingenix uses encrypted unique patient identifiers to integrate laboratory results, pharmacy, and medical claims data.
Subject Inclusion Criteria and Study Timeline
An index date was defined as the first indicator of hyperlipidemia between January 1, 1999 and March 31, 2001 ( Fig. 1 ). Indicators of hyperlipidemia included the presence of a hyperlipidemia diagnosis on a medical claim (ICD-9-CM codes: 272.0x-272.2x, 272.4x, or 272.9x) or any prescription claim for a lipid-lowering medication (LLM) (therapeutic niacin, fibric-acid derivatives [FAD], bile acid sequestrants [BAS], or HMG-CoA reductase inhibitors [statins]) during the capture period. Subjects were not required to have an LLM claim to be identified as hyperlipidemic, and LLM use may have begun after the index date. Subjects were defined as new hyperlipidemic subjects based on an absence of a hyperlipidemia diagnosis and LLM use in the 24 months before the index date. Health-care resource utilization data records 12 months after the index date were analyzed to assess outcomes. Subjects were required to be continu-ously enrolled in their health plan for 24 months before and 12 months after the index date.
Established CHD or Moderate-High CHD Risk Factors and LDL-C Goals
Subjects were categorized into two risk groups based on health-care resource utilization data in the 24month period before the index date. Subjects with CHD, diabetes, or other forms of atherosclerotic disease (acute myocardial infarction, other acute and subacute forms of ischemic heart disease, angina pectoris, other forms of chronic ischemic heart disease, stroke, peripheral vascular disease, and atherosclerosis) were considered to be at high risk for CHD. Subjects with ≥2 CHD risk factors (i.e., history of smoking or current smoker, hypertension, low HDL cholesterol (<40 mg/dL), family history of ischemic heart disease, and age (male ≥45; female ≥55 years of age) were considered at moderate risk for CHD. HDL ≥60 counts as a negative risk factor: its presence removes one risk factor from the total count. Subjects without an established CHD, a CHD-related condition, or two or more CHD risk factors were excluded from the analyses.
Because the full 10-year Framingham risk score cannot be calculated using administrative data, we assigned ATP III LDL-C goals of <100 mg/dL and <130 mg/dL to the high-and moderate-risk groups, respectively, using available ICD-9 codes and pharmacy claim records in the 24 months before the index date.
Lipid-Lowering Medication Classification
The objectives of the study were to examine the effectiveness of LLM medications by assessing the LDL-C reductions achieved in actual managed care practice setting and to compare the level of LDL-C reduction to RCT results. To facilitate this analysis, mutually exclusive statin medication groups were defined based, in part, on the magnitude of expected percent reduction in LDL-C levels ascertained from the package insert for each drug. Subjects were categorized into efficacy categories (Table 1) based on prescription claims in the 12 months after the index date. Subjects in the low, moderate, and high statin efficacy categories were required to have a minimum level of adherence of the same statin and efficacy dose. Subjects assigned to these statin efficacy categories must have had at least two statin prescription claims with no more than 90 days between prescriptions based on a 30-day supply. Subjects with other statin use were categorized separately, including subjects with single statin prescriptions, a greater than 90-day gap in statin treatment, prescriptions from multiple efficacy categories, or combination therapy with nonstatin LLMs (therapeutic niacin, FAD, or BAS). Subjects with only nonstatin LLMs were categorized as "other LLM use." Subjects without LLM use were also classified separately resulting in six LLM categories: low efficacy statins, moderate efficacy statins, high efficacy statins, nonadherent statin use, other LLM use, and no LLM use. 
Subject Characteristics and LLM Utilization
Demographics (age and sex) were obtained for each subject. The utilization of each type of LLM was measured in terms of number of claims, the proportion of subjects with use of multiple LLMs or multiple statins, the proportion of subjects increasing their initial dose of LLMs, and the proportion of subjects with use of the highest dose available of any particular statin in the 12-month period after the index date.
Cholesterol Values
Baseline and post-treatment cholesterol test results were determined for each subject. In the presence of multiple test results, the most recent test result before the index date (up to 12 months before the index date) was used for the baseline test value and the results from the test that occurred the farthest from the index date (up to 12 months after the index date) was used for the post-treatment test value. The minimum time period after initiation of lipid-lowering therapy and first post-treatment LDL-C value was 4 weeks (28 days). If the index date reflected a diagnosis and not medication initiation, then the minimum number of days was imposed from the start of new drug therapy. For subjects with no LLM use, the minimum time until a post LDL-C value was determined from the index date. HDL-C values were used to assess a subject's CHD risk status whereas LDL-C values were used to determine the effect of treatment and subjects' ability to reach ATP III goals. The absolute change in LDL-C, the percent change in LDL-C, and the subjects reaching their ATP III goals was determined for all subjects.
Statistical Analysis
Subject demographics and the utilization of LLM therapy was summarized and described using frequency distributions and bivariate techniques. Age was examined across LLM categories using an ANCOVA model and a Ryan-Einot-Gabriel-Welsch multiple range test [25] at a significance level of alpha = 0.05. Sex was examined similarly using a Cochran-Mantel-Hanzsel Chi-Square test [25] . We descriptively examined the proportion of subjects, overall and in each risk group by LLM category. Changes in LDL-C levels for each statin efficacy category were compared with the expected result based on product labeling. Statistical comparisons were made across LLM categories using a multiple regression model. Additionally, the proportion of subjects meeting their ATP III-established LDL-C goal was compared across LLM categories using a logistic regression model. Included in the statistical equations were variables indicating the LLM categories (no LLM use was the reference group), age, sex, the level of CHD risk (moderate or high), the baseline (BL) LDL-C value, an indicator variable for obesity (ICD-9278.0x) and the natural log of the preindex total health-care cost. A log transformation was used to correct the skewed distribution of health-care costs. Total health-care cost is a proxy for total health-care utilization and commonly used as an approximation a subject's overall morbidity burden-adding this variable to the model helps to control for any differences in the population that may affect the ability to reach an LDL-C goal other than the use of LLMs [26] [27] [28] . The reference group for the medication categories was the no LLM use category. All statistical tests used a significance level of alpha = 0.05.
Results
Study Population Characteristics
We identified 39,124 newly indicated hyperlipidemic subjects, ≥18 years of age, considered at high or moderate risk for CHD as previously defined. The majority of subjects were male (61.9%) and most were enrolled in health plans in the south Atlantic (30.2%), east north central (36.8%) and west north central (20.5%) United States. The average age was 53.9 years (range: 18-92 years). The majority (n = 22,048, 56.4%) of at-risk subjects had no LLM use in the 12-month follow-up period ( Table 2) . Female subjects, younger individuals, and individuals with fewer CHD risk factors and/or fewer chronic conditions were less likely to be on LLMs. Categorization. The 17,076 LLM-treated subjects were classified into five LLM categories (Table 2) . Approximately 61% (n = 10,403) of LLM-treated subjects were categorized into statin efficacy categories. Approximately 51% (n = 8688) of the LLM users were classified into the moderate efficacy statin category; 6.7% (n = 1138) were classified into the high efficacy statin category and 3.4% (n = 577) were classified into the low efficacy statin category. Thirty percent (29.5%) of LLM-treated subjects (n = 5033) had other statin use and 9.6% (n = 1640) were strictly nonstatin LLM-treated subjects. Of the 5033 subjects with nonadherent statin use, 40.5% (n = 2038) had a single statin prescription, 5.1% (n = 255) had greater than a 90-day gap between statin prescriptions, 37.5% (n = 1886) had multiple efficacy statin prescriptions, and 17.0% (n = 854) had a combination of statin and nonstatin prescriptions.
Lipid-Lowering Medication Use
Based on the entire sample of moderate-to high-CHD risk subjects with an indication of hyperlipidemia (n = 39,124), approximately 2.9% of the subjects were categorized into the high-efficacy statin group, 22% in the moderate-efficacy group, 1.5% in low-efficacy group, 13% in the other statin group, 4.2% were other LLM users, and 56% had no LLM use.
Titration. Overall, 2658 of LLM-treated subjects (15.6%) increased their statin dose either within a statin efficacy category (n = 478) or titrated up to a higher efficacy statin category (n = 2079). Of the 2079 subjects who titrated up to a higher efficacy statin category, most subjects (n = 1611, 77.5%) moved from a moderate efficacy statin to a high efficacy statin. Within statin efficacy categories, the up-titration was most common in the high-efficacy statin category (10.4%, n = 107) compared with 4.1% (n = 355) and 2.8% (n = 16) in the moderateand low-efficacy statin categories, respectively. Despite the fact that a number of subjects uptitrated their statin dose, a small percentage of subjects (266 of 15,436 statin users, 1.7%) were uptitrated to the maximum statin dose. Similarly a small percentage of subjects (394, 2.3%) had prescriptions for a maximum LLM dose.
Demographics.
A higher percentage of males was observed across LLM groups compared with females. Nevertheless, a significantly lower percentage of males were in the "untreated" category compared with the other groups (P < 0.05). Lowefficacy statin users were significantly older than moderate efficacy statin users; and moderate efficacy statin users were significantly older than all other LLM groups, except low efficacy statin users (P < 0.05).
LDL-C Test Results and Reductions in LDL-C
Across LLM categories, 964 (2.5%) had results both in the preindex and postindex periods and 2718 (6.9%) had a post or follow-up result ( Table 3 ). Subjects with LLM use had a higher percentage of postindex results compared with untreated subjects and statin users had a higher percentage of both baseline and postindex results compared with nonstatin and untreated subjects. Based on the subset of 2718 subjects with an LDL-C result, the mean baseline LDL-C value was 148 mg/ dL and the mean follow-up value was 116 mg/dL (mean follow-up was 108 mg/dL for 964 subjects with BL LDL-C value) A separate analysis was conducted comparing the characteristics of subjects with and without an LDL-C lab result. There were slight variations in geographic region, however, no significant differences were observed in mean age, percent male, number of specialty types, CHD risk, and baseline health-care cost. Subjects with a baseline LDL-C value already at goal (6.3%) were removed from the ATP III goal analysis. Subjects had a mean interval between their first LLM prescriptions and their latest LDL-C value (the test value used to assess the effectiveness of LLM therapy) of 215 days (SD 100 days, median 226 days). For the 964 subjects with a baseline and follow-up LDL-C value, the mean change from baseline was -39.8 mg/dL and the mean percent change from baseline was a 22.9% decrease in mg/dL. Baseline LDL-C values were highest for statin users and lowest for nonstatin-treated subjects. Among all statin users, mean baseline LDL-C levels ranged from 149 to 164 mg/dL compared with subjects with other LLM use (mean 109.6 mg/dL) and subjects with no LLM use (mean 133.6 mg/dL). Subjects treated with statin therapy had a greater change and percent change from baseline in LDL-C values compared with nonstatin LLM users and non-LLMtreated subjects. The statin-treated groups had absolute reductions ranging from a mean decrease of 32.3 mg/dL in the low-efficacy statin group to a decrease of 57.3 mg/dL in the high-efficacy statin group. Percent reductions ranged from a 19.1% to a 31.6% reduction from baseline. The mean percent reduction for the high-and moderate-efficacy statin group was below expectations based on package labeling. The median percent change from baseline of a 37.0% decrease in mg/dL for the high-efficacy subject states that less than half the subjects in this group met the expected reduction of >41%. The absolute reductions and percent reductions in the high-and moderate-efficacy groups were approximately twice as high as those in the non-LLMtreated subjects. The nonstatin LLM-treated subjects had, on average, an increase in LDL-C levels from baseline; though many (22.8%) nonstatin LLM-treated subjects were below ATP III goals before LLM initiation (mean baseline LDL-C: 109.6 mg/dL). Table 3 also presents the leastsquares (LS) mean percent reductions in LDL-C adjusted for other variables in an ANOVA model. The LS mean reductions for the high-efficacy and moderate-efficacy statin groups were greater (more negative) than the LS mean for the non-LLMtreated group, whereas the LS means of the low-efficacy, other statin, and other LLM groups were less negative that the non-LLM-treated group LS mean. In the regression model (Table 4 ), the dependent variable was change from baseline and because a greater negative value was favorable, a negative parameter estimate indicates a positive association with reduction in LDL-C. Subjects in the moderateefficacy statin groups had significantly greater percent reduction from baseline compared with the non-LLM-treated group (est = -0.040, P = 0.0376). The estimate for the high-efficacy group was negative suggesting a greater percent reduction than the non-LLM-treated group, but the statistical test was not significant (P = 0.6644). Based on alpha = 0.05 and power = 0.80, a sample size of approximately 150 per treatment arm would be needed to show a significant reduction of 10% in this study. The non-LLM use group had a significantly greater percent reduction in LDL-C compared with the other statin use and the other LLM use groups. Also in this model, males had an approximately 0.7% greater percent reduction in LDL-C compared with females (est = -0.069, P < 0.0001), an increase in age was associated with a greater reductions in LDL-C (est = -0.002, P = 0.0211), a higher BL LDL-C value was associated with a greater reductions in LDL-C (est = -0.004, P < 0.0001), and a lower ATP III goal was associated with a greater LDL-C reduction (est = -0.032, P = 0.0467). For the subjects without BL LDL-C values, the mean BL LDL-C value within the efficacy group was used in this analysis.
Risk Factors and LDL-C Goal
Fifty-six percent of subjects (21,930 of 39,124) had either a CHD or a CHD-equivalent condition in their medical claims, and therefore had an LDL-C goal of <100 mg/dL ( Table 2 ). The remaining 43.9% (17, 194 of 39,124), had two or more CHD risk factors and therefore had a goal of <130 mg/ dL. Of the subjects with LLM therapy, a similar percentage (63%-65%) in each LLM category had either an established CHD or CHD-equivalent condition, in contrast to the group of subjects with no LLM therapy, in which 50% of subjects had an established CHD or a CHD-equivalent condition.
Subjects reaching ATP III LDL-C goal. Less than half of subjects for whom laboratory results were available reached ATP III goals (46.8% [1191 of 2718]) (bottom half of Table 3 ). A greater proportion of subjects in the high-efficacy category reached goal (71.6% vs. 43.1%) compared with other drug efficacy groups (including the non-LLM group).
There was a graded association between statin efficacy level and the proportion of subjects reaching goal with more efficacious treatment leading to more successful outcomes. Low-efficacy statin users had a similar percentage of subjects reaching goal (43.4%) compared with the other statin users (44.4%) and the other LLM users (45.9%). For the non-LLM use group, 38.2% had LDL-C levels within goal. In the logistic regression analysis (Table 5) , the high-efficacy, moderate-efficacy, and other statin groups had significantly higher odds of subjects reaching their ATP III LDL-C goal compared with subjects with no LLM use (P < 0.05). High-efficacy statin users were more than four times more likely to reach goal then non-LLM-treated subjects. The odds of reaching goal increased as statin efficacy increased. Also in the model, males were more likely to reach goal than females (odds ratio [OR] = 1.256, P = 0.0112), a higher BL LDL-C value was associated with lower odds of reaching goal (OR = 0.994, P = 0.0189), a lower ATP III goal was associated with lower odds of reaching goal (OR = 0.291, P < 0.0001), and a higher baseline total health-care cost increases the likelihood of reaching goal (unit increase in cost OR = 1.112, P < 0.0001).
Within-risk-group analysis. Table 6 provides a subset analysis of the percentage of subjects reaching ATP III LDL-C goals by risk category. In this descriptive analysis, a higher percentage of subjects at moderate risk for CHD (goal <130 mg/dL) reached goal than high-risk subjects (goal <100 mg/ dL) (55.2% vs. 36.3%). In the high-risk subjects, the proportion of subjects reaching goal increased with more aggressive treatment, however, a linear pattern was not observed in the moderate-risk group. Table 6 shows that approximately 45% (26 of 47) of high-risk subjects who were treated with high-efficacy medication did not reach a goal of <100 mg/dL and more than half of each the other LLM-treated subjects in the high-risk group did not reach this goal. Of subjects with available laboratory values who were in the high-risk group, 39% (604 of 1541) were not treated with LLMs. 
Inconsistent Statin Use
Of the subjects with a baseline LDL-C values, 35.9% (346 of 964) of subjects needed at least a 30% reduction in LDL-C value to meet their goal. Only 53.5% (185 of 346) of the subjects received either moderate-or high-efficacy statins. Approximately 16% of subjects needed at least a 40% reduction in LDL-C value to meet their goal and only 2.0% (3 of 149) of the subjects received highefficacy statins. Notably, 50% of subjects who were identified as being at high risk for CHD (as defined by ATP III) had no evidence of LLM use.
Discussion
The main findings of this study were the lack of effectiveness of statin therapy and undertreatment among high-risk individuals. Effectiveness of a medication may be due to the insufficient potency of a medication as well as a lack of adherence. Medication adherence analyses were reported by Frolkis and colleagues suggesting that variability in patient adherence may contribute to the lack of expected LDL-C reductions [24] . We used a methodology to categorize subjects into medication groups that required a minimum level of adherent statin use, yet the resulting effectiveness was below LDL-C reductions stated in the package labeling. Approximately 30% of the statin users did not meet our adherence requirements, and the medication possession ratio (MPR = total days supply in the year follow-up divided by 365 days) of the statin efficacy groups ranged from 59% to 65%, compared with an MPR of 50% for the other statin use group and an MPR of 46% for the other LLM use group. The lack of effectiveness-ability of statin medications in realworld observations to achieve the observed efficacy reported in clinical trials-may be a result of underprescribing of the appropriate strength of therapy, but may also be due to adherence to medications. Previous research has also noted the failure of subjects in clinical practice settings to achieve expected reductions in LDL-C when treated with statin therapy [8, 9, 13] . Subjects enrolled in protocol-driven RCTs have scheduled visits and are carefully screened, monitored closely, and are likely to have higher medication compliance than that seen in a real-world setting.
Retrospective cohort studies using administrative claims data enhanced with laboratory results can be used to supplement clinical trials data and to enhance the generalizability of the findings to realworld practice. In this study, the mean baseline LDL-C value was 148 mg/dL and the mean followup value was 116 mg/dL. This mean baseline value was higher than the mean value of LDL-C for all US adults reported by NHANES III of 127 mg/dL [1] , although this NHANES figure represents all US adults, whereas the baseline mean LDL-C in this study was among moderate to high CHD risk subjects.
The percent change in LDL-C reduction results suggests that the lack of effectiveness appears to be more evident in the high-efficacy statin users and the unmet need appears to be more evident in the high-risk population. In the three statin efficacy groups that required a minimum level of adherence, a dose-response relationship was observed, but less than half of subjects in the high-efficacy group achieved LDL-C reductions stated in the package labeling and only 68% reached their LDL-C goal during a one-year follow-up period. While the subset of subjects with an existing CHD or CHDequivalent condition that received statin therapy achieved reductions in LDL-C values consistent with package labeling, less than 60% of the highefficacy statin users reached their ATP III goal of <100 mg/dL and less than 50% of other statin groups reached goal. More strikingly, only 50% of subjects with CHD or CHD-equivalent conditions received LLMs and less than 30% of subjects with CHD or CHD-equivalent conditions had statin therapy consistent with our definitions of the statin efficacy categories. This study was based on ATP III guidelines in which one of the new features was to include persons with diabetes to the risk level of CHD risk equivalent. The high proportion of subjects without LLM use in the subset of subjects with an existing CHD or CHD-equivalent condition may be a result of this new ATP III feature. The average age of the subset of subjects with an existing CHD or CHD-equivalent condition was 52.8 years of age compared with an average age of 55.2 years in the subset of subjects with two or more CHD risk factors also suggests that a younger set of persons with diabetes were included in this group.
The ATP III guidelines created a greater need for lipid-lowering therapy for high-risk patients and these results suggest that this need is unmet. A previous study (Dubois et al.) , also based on ATP III guidelines, concluded that there did not appear to be extended use of statins in a population with lower cardiovascular risk [29] . Therefore, efforts to increase the use of stain therapy appear to be focused appropriately on the higher-risk patients, though many high-risk patients still fail to receive treatment or adequate treatment.
This retrospective study has several limitations. First is the possibility of misclassification of new hyperlipidemic subjects and the determination of ATP III goals. To be included in the study subjects had to be free of hyperlipidemia before January 1, 1999. Because we had information on prescription claims and disease diagnoses for a 24-month period before first indication of a hyperlipidemia diagnosis or initial LLM use (index date), we did not have laboratory values before January 1, 1999 and the lack of information on HDL levels may have affected the assessment of risk factors and ATP III goals. We used actual lipid values and diagnoses on nonlaboratory claims to classify hyperlipidemic subjects and their risk level. It is unlikely that a subject would be classified as a false positive and therefore the incidence of hyperlipidemia and the level of CHD risk would, if anything, be under-reported. Underreporting the level of risk would only accentuate the issue of undertreatment. Second, a limitation common to most studies using administrative claims data and laboratory results was the lack of cholesterol laboratory values for a large proportion of the sample. Of the 43.6% (17,076 of 39,124) of subjects that received LLMs, 9.1% (1550 of 17,076) had LDL-results after medication initiation. Only 2.5% (964 of 39,124) had both pre-and posttreatment LDL-C results. We examined the populations with and without lab values and found that similar characteristics existed in terms of age, sex, obesity, and CHD risk; however, the subjects without lab values had lower LLM adherence than the subjects with lab values. This would lead us to believe that the level of LLM effectiveness is worse than reported in this study. This is a major limitation of the study and while further research with larger samples is suggested, these results do suggest an issue with lack of LLM effectiveness and undertreatment. Finally, the study requirement of 36 months of continuous enrollment may have limited generalizability (i.e., to those with chronic conditions unlikely to switch health plans, those who survived, and older subjects).
Conclusions
The results of this real-world study of the effectiveness of statin therapy are consistent with previously reported findings that hyperlipidemia management needs further improvement [8] [9] [10] [11] [12] 29] . The reductions in LDL-C values in subjects treated with statins generally follow a dose-response relationship, but there are concerns with the high percentage of untreated high-risk subjects, the effectiveness of the strongest statin doses in achieving desired LDL-C reductions and getting to goal, and the insufficient amount of dose titration, especially from the lowerefficacy agents. There is evidence of a need for more extended use of statin therapy in populations with higher cardiovascular risk and for more efficacious agents on which subjects can reach their cholesterol goal at the starting dose, without the need to titrate or augment with combination therapy.
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